Shire PLC , which in-licenses marketed or close-to-market drugs in specialist areas, has been one of the industry's fastest-growing firms, driven by an aggressive acquisition strategy and strong marketing.
But shareholders are becoming disenchanted. In the first place, the firm's most important product, Adderall, a mixture of four amphetamine...




